Related Experiment Video
Updated: Aug 7, 2026
05:04
Using Simulation Models to Train Clinicians in the Use of Point-of-Care Ultrasound
Published on: August 9, 2024
Five-year clinical experience with the Dornier Delta lithotriptor
Wesley White1, Frederick Klein
1Department of Urology, University of Tennessee Medical Center, Knoxville, Knoxville, Tennessee 37920, USA. wwhite@mc.utmck.edu
Urology
|June 17, 2006
Summary
The Dornier Delta lithotriptor effectively treats kidney and ureteral stones, achieving an 85.1% success rate. This extracorporeal shock wave lithotripsy (ESWL) device demonstrates comparable efficacy to other lithotriptors for urolithiasis management.
Area of Science:
- Urology
- Nephrology
- Medical Devices
Background:
- Extracorporeal shock wave lithotripsy (ESWL) is a valuable treatment for symptomatic urolithiasis.
- Previous studies have assessed various lithotriptors, but efficacy data for the Dornier Delta device were lacking.
Purpose of the Study:
- To evaluate the efficacy and outcomes of the Dornier Delta lithotriptor in treating patients with urolithiasis.
- To establish the success rate and complication profile of this specific lithotriptor.
Main Methods:
- A retrospective review was conducted on 4621 patients treated with the Dornier Delta lithotriptor between 1999 and 2004.
- Data collected included stone characteristics (location, size), shockwave parameters, success rates, and complications.
Main Results:
- The study analyzed 7347 stones, with 74.38% in the kidney and 25.62% in the ureter.
- The overall success rate was 85.1%, with 58.5% stone-free and 26.6% achieving fragments < 4 mm.
- The efficiency quotient was 0.51, with an average of 2037 shocks and treatment time of 23.8 minutes.
Conclusions:
- The Dornier Delta lithotriptor is a suitable option for treating selected renal and/or ureteral stones.
- Its total success rate and efficiency quotient align with those of other commercially available lithotriptors.